Q1 2019 Earnings Forecast for Amedisys Inc (AMED) Issued By Oppenheimer
Amedisys Inc (NASDAQ:AMED) – Oppenheimer issued their Q1 2019 EPS estimates for Amedisys in a research note issued to investors on Tuesday. Oppenheimer analyst M. Wiederhorn expects that the health services provider will post earnings of $0.63 per share for the quarter. Oppenheimer also issued estimates for Amedisys’ Q2 2019 earnings at $0.71 EPS, Q3 2019 earnings at $0.71 EPS, Q4 2019 earnings at $0.74 EPS and FY2019 earnings at $2.79 EPS.
Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Amedisys from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Royal Bank of Canada restated a “hold” rating on shares of Amedisys in a report on Monday, October 23rd. Mizuho restated a “buy” rating and issued a $65.00 target price (up from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. William Blair restated an “outperform” rating on shares of Amedisys in a report on Tuesday, November 21st. Finally, SunTrust Banks restated a “buy” rating and issued a $70.00 target price on shares of Amedisys in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and a consensus price target of $61.00.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The business had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 earnings per share.
A number of institutional investors have recently added to or reduced their stakes in AMED. Riverhead Capital Management LLC grew its holdings in Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after purchasing an additional 831 shares during the period. Federated Investors Inc. PA lifted its position in Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in Amedisys during the third quarter valued at approximately $205,000. Amalgamated Bank acquired a new position in Amedisys during the second quarter valued at approximately $246,000. Finally, NorthCoast Asset Management LLC acquired a new position in Amedisys during the third quarter valued at approximately $262,000. Hedge funds and other institutional investors own 94.50% of the company’s stock.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.